FDA approves first treatment for Alzheimer's disease Dr. Kamal Kant Kohli8 July 2023 11:00 AM ISTThe US Food and Drug Administration has granted full approval to Lecanemab (Leqembi) as first Alzheimer's treatment targeted at the disease...
Eisai seeks marketing nod for Lecanemab for early Alzheimer's disease treatment in South Korea Ruchika Sharma11 Jun 2023 12:45 PM ISTLecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of...
Eisai seeks marketing authorisation for Lecanemab to treat early Alzheimer's disease in Great Britain Ruchika Sharma23 May 2023 11:00 AM ISTLecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of...
Eisai-Biogen Alzheimer's drug Lecanemab should be priced below Aduhelm: Report Ruchika Sharma25 Dec 2022 2:00 PM ISTTreatment with the drug may provide a small or even substantial benefit to patients with early Alzheimer's, but there remains a possibility of net...
Lecanemab improves function and cognition in early Alzheimer's disease: NEJM Medha Baranwal5 Dec 2022 11:15 AM ISTUSA: In patients with early Alzheimer's disease, lecanemab reduced amyloid markers and led to a moderately less decrease in measures of cognition and...
Roche to stop all Gantenerumab studies in early Alzheimer's disease Ruchika Sharma2 Dec 2022 2:30 PM ISTRoche is still testing a different formulation of gantenerumab called trontinemab, designed to ferry the drug across the blood brain barrier -...
USFDA decision on Eisai, Biogen Alzheimer's drug due in January Ruchika Sharma6 July 2022 10:00 AM ISTEisai in March downsized its role in Aduhelm, but remains the leader in the 50-50 partnership's lecanemab program.
Biogen gets USFDA Fast Track designation for lecanemab Ruchika Sharma26 Dec 2021 9:30 AM ISTTokyo: Eisai Co., Ltd. and Biogen Inc. have announced that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the...
